Theriva Biologics, Inc. (TOVX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TOVX Revenue Growth
TOVX Revenue Analysis (2014–2025)
As of May 8, 2026, Theriva Biologics, Inc. (TOVX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue.
Looking at the longer-term picture, TOVX's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including NKTR (-43.9% YoY), AGEN (+10.4% YoY), and IMMP (+54.3% YoY). Compare TOVX vs NKTR →
TOVX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TOVXCurrent | $0 | - | - | - | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 IMMP | $5M | +54.3% | -7.6% | -2506.5% |
TOVX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-108,000 | - | $-15,020,000 | - |
| 2024 | $0 | - | $0 | - | $-26,346,000 | - |
| 2023 | $0 | - | $0 | - | $-21,431,000 | - |
| 2022 | $0 | - | $0 | - | $-21,581,000 | - |
| 2021 | $0 | - | $0 | - | $-14,274,000 | - |
| 2020 | $0 | - | $0 | - | $-10,160,000 | - |
| 2019 | $0 | - | $0 | - | $-15,663,000 | - |
| 2018 | $0 | - | $-272,000 | - | $-17,571,000 | - |
| 2017 | $0 | - | $-245,000 | - | $-26,251,000 | - |
| 2016 | $0 | - | $-157,000 | - | $-39,252,000 | - |
See TOVX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TOVX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TOVX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTOVX — Frequently Asked Questions
Quick answers to the most common questions about buying TOVX stock.
Is TOVX's revenue growth accelerating or slowing?
TOVX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is TOVX's long-term revenue growth rate?
Theriva Biologics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is TOVX's revenue distributed by segment?
TOVX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.